| Old Articles: <Older 3221-3230 Newer> |
|---|
 |
The Motley Fool
October 26, 2006
Brian Lawler |
QLT Quickly Losing Traction The biotech company gets hammered by a competitor's superior product. There was one bright spot in the quarter for QLT, though. Investors, take note.   |
The Motley Fool
October 25, 2006
Brian Lawler |
The Medicines Company's Heartening Results At today's share price, investors are almost getting the upside associated with TMC's developmental drug pipeline for free, when combined with the sales growth and expanded opportunities available with Angiomax. That should be a hard deal to pass up for patient investors. |
The Motley Fool
October 25, 2006
Brian Lawler |
Earnings Soothe ImClone Investors For long-term shareholders of ImClone stock, it will be hard to bask in the glory of ImClone's positive earnings for long. Numerous looming issues surround the company, including the Yeda patent dispute, coming competition from Amgen's Vectibix, and possible shareholder shenanigans from Icahn. |
The Motley Fool
October 24, 2006
Brian Lawler |
Playing the AtheroGenics Waiting Game The results of phase 3 trials for the company's atherosclerosis drug will determine AtheroGenics' future. Investors, take note. |
The Motley Fool
October 23, 2006
Michael P. Cecil |
Are Pacemaker Prices Heading for a Fall? Medicare law changes may drive the amount that hospitals can pay for pacemakers. Will device makers be forced to lower prices? Investors, take note. |
BusinessWeek
October 30, 2006
Arlene Weintraub |
ETFs That Target Disease New baskets of stocks let investors bet on medical breakthroughs |
InternetNews
October 20, 2006
Roy Mark |
'Net Vendors of Diabetes Cures on Notice The Federal Trade Commission and the Food and Drug Administration are teaming with Mexico and Canada to stop deceptive advertising and product sales of purported diabetes cures and treatments. |
The Motley Fool
October 20, 2006
Brian Lawler |
Lilly Pads Its Earnings Lilly reports third-quarter 2006 numbers and gobbles up Cialis. Investors, take note. |
The Motley Fool
October 20, 2006
Brian Lawler |
Cubist Paints a Greener Picture The pharmaceutical company is flush with cash and finally profitable. However, it might just be easier for Cubist to sell itself to a more substantial pharmaceutical company. Investors, take note. |
The Motley Fool
October 20, 2006
Brian Lawler |
Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth. |
| <Older 3221-3230 Newer> Return to current articles. |
